Access. Assistance. Along the Journey.
Exelixis Access Services® (EASE) provides a variety of support to help your patients get started on treatment as soon as possible. EASE can meet the unique needs of your patients and practice at each step along the access journey.
HELP YOUR PATIENTS GET STARTED ON CABOMETYX® (cabozantinib)
Your EASE Case Manager
EASE offers regionally dedicated Case Managers as a single point of contact.
- Can provide the status of your patient's access journey
- Offers prompt support with payer coverage, financial assistance, and treatment coordination
- Provides proactive follow-up
Monday to Friday, 8:00 AM to 8:00 PM ET
Enroll your eligible patients in one of two ways
Complete and submit the EASE enrollment form available on this page.
Access and submit a prior authorization request for CABOMETYX through CoverMyMeds®. Enroll eligible patients in EASE services at the same time. Click on the link to the right to access the online tool.
PROGRAMS TO HELP PATIENTS START AND STAY ON CABOMETYX
Provides free drug to help patients start treatment quickly.*†
Provides free drug to eligible patients who experience a payer decision delay of 5 days or more.*†
Eligible commercially insured patients pay $0 per month, for a maximum benefit of $25,000 per year.†
Provides a free 15-tablet supply in the lower dose to help patients who require a dose reduction.†
Eligible patients who cannot afford their drug costs may receive CABOMETYX free of charge.†
SUPPORT FOR COVERAGE DETERMINATION
At your request, EASE can provide support with:
- Benefits investigation
- Prior authorization (PA) assistance
- Appeals support and follow-up
*Limited to on-label indications. Additional restrictions and eligibility rules apply.
†Additional restrictions and eligibility rules apply.
This description of the Exelixis Access Services® (EASE) program is for informational purposes only. Exelixis* makes no representation or guarantee concerning reimbursement or coverage for any service or item. Information provided through the Exelixis Access Services program does not constitute medical or legal advice and is not intended to be a substitute for a consultation with a licensed healthcare provider, legal counsel, or applicable third-party payer(s). Exelixis reserves the right to modify the program at any time without notice.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) support the use of cabozantinib (CABOMETYX) in the treatment of both aRCC and HCC
National Comprehensive Cancer Network® (NCCN®)
Cabozantinib (CABOMETYX) is THE ONLY NCCN "PREFERRED" SINGLE-AGENT TKI option for 1L intermediate/poor risk clear cell aRCC1
Cabozantinib (CABOMETYX) is THE ONLY NCCN "PREFERRED" SINGLE-AGENT TKI option for 2L clear cell aRCC1
As defined by the NCCN Guidelines®, preferred interventions are based on superior efficacy, safety, and evidence; and when appropriate, affordability.
*Data reﬂect use after sorafenib. Lenvatinib is recommended by the NCCN as a ﬁrst-line systemic therapy option, but there are no data to deﬁne optimal treatment for those who progress on lenvatinib.2
Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
aRCC=advanced renal cell carcinoma; HCC=hepatocellular carcinoma; TKI=tyrosine kinase inhibitor.